Mark Colligan, MD
Cardiovascular Disease · San Antonio, TXNPI 1902998347
Payments from drug & device makers
Across 524 payments — averaging $245.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$57K
- Amgen$35K
- Sanofi-aventis U.S. LLC$13K
- E.r. Squibb & Sons, L.L.C.$6K
- Regeneron Healthcare Solutions, Inc.$5K
- Pfizer$4K
- plus $10K from 25 others
What the payments were for
- Speaking & faculty fees$99,76978%
- Travel & lodging$13,75011%
- Food & beverage$15,10512%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 67 | $56,714 |
| Amgen | 46 | $34,888 |
| Sanofi-aventis U.S. LLC | 12 | $12,503 |
| E.r. Squibb & Sons, L.L.C. | 53 | $6,091 |
| Regeneron Healthcare Solutions, Inc. | 20 | $4,526 |
| Pfizer | 100 | $3,791 |
| Medtronic(2 entities) | 30 | $2,898 |
| Abbott | 38 | $1,425 |
| Johnson & Johnson | 28 | $1,217 |
| Abiomed | 7 | $755 |
| Novartis | 44 | $714 |
| Irhythm Technologies, Inc. | 21 | $424 |
| Alnylam Pharmaceuticals Inc. | 7 | $354 |
| Biotronik Inc. | 6 | $295 |
| Veryan Medical Incorporated | 3 | $266 |
| Boston Scientific | 12 | $265 |
| Amarin Pharma, Inc. | 4 | $262 |
| Boehringer Ingelheim | 4 | $188 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $178 |
| Inari Medical, Inc. | 1 | $173 |
| Novo Nordisk | 1 | $140 |
| Shockwave Medical, Inc | 2 | $134 |
| Regeneron | 1 | $123 |
| Braemar Manufacturing, LLC | 1 | $90 |
| AstraZeneca | 1 | $57 |
| Actelion Pharmaceuticals US, Inc. | 1 | $39 |
| Acist Medical Systems, Inc. | 1 | $37 |
| Lexicon Pharmaceuticals, Inc. | 1 | $29 |
| Osprey Medical Inc | 1 | $27 |
| Lantheus Medical Imaging, Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLETOL$55,669
- NEXLIZET$55,544
- Repatha$34,233
- PRALUENT$16,323
- ELIQUIS$8,305
- Micra$1,328
- XARELTO$848
- Impella$677
- LINQ II$505
- BioMimics 3D Vascular Stent System$258
- CARDIOMEMS$250
- Vascepa$250
- ONPATTRO$248
- FLOWTRIEVER CATHETER, S$173
- CT THROMBECTOMY SYSTEM KIT$173
- AVEIR$148
- Wegovy$140
- SelectSecure$134
- JARDIANCE$125
- Reveal LINQ$122
How this compares
$128,644 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 846 | $1,011,512 |
| XareltoRivaroxaban | 327 | $414,916 |
| EntrestoSacubitril/Valsartan | 137 | $155,266 |
| FarxigaDapagliflozin Propanediol | 77 | $65,176 |
| Repatha SureclickEvolocumab | 78 | $61,545 |
| NexlizetBempedoic Acid/Ezetimibe | 41 | $31,219 |
| Praluent PenAlirocumab | 42 | $28,485 |
| MultaqDronedarone Hcl | 15 | $24,769 |
| JardianceEmpagliflozin | 18 | $16,483 |
| NexletolBempedoic Acid | 12 | $10,662 |
| Ezetimibe | 444 | $10,553 |
| Rosuvastatin Calcium | 820 | $10,063 |
| VascepaIcosapent Ethyl | 18 | $9,871 |
| Metoprolol Succinate | 522 | $7,851 |
| Chlorthalidone | 393 | $7,348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $3,791 | $1,011,512846 claims |
| Johnson & JohnsonXarelto | $1,217 | $414,916327 claims |
| NovartisEntresto | $714 | $155,266137 claims |
| AstraZenecaFarxiga | $57 | $65,17677 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $56,714 | $41,88053 claims |
| Sanofi-aventis U.S. LLCMultaq | $12,503 | $24,76915 claims |
| Boehringer IngelheimJardiance | $188 | $16,48318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in San Antonio
- Chandrasekhar KunavarapuSan Antonio$765K
- Robert SchnitzlerSan Antonio$425K
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.